Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher
Osmotica Pharmaceuticals plc OSMT was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $5.09 –$6.99 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Osmotica Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
OSMOTICA PHARM Price
OSMOTICA PHARM price | OSMOTICA PHARM Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Akcea Therapeutics Inc AKCA, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
OSMOTICA PHARM (OSMT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
